Radiotherapy in prostate cancer after kidney transplant in 6 cases.


Journal

Tumori
ISSN: 2038-2529
Titre abrégé: Tumori
Pays: United States
ID NLM: 0111356

Informations de publication

Date de publication:
Aug 2022
Historique:
pubmed: 1 6 2021
medline: 23 7 2022
entrez: 31 5 2021
Statut: ppublish

Résumé

Patients who received a kidney transplant (KT) are described in literature as a group with a higher incidence of malignant neoplasms compared to the general population. Cancer development after KT has become a major issue, as a remarkable percentage of patients are diagnosed with cancer. Treatment of prostate cancer (PCa) in renal transplant recipients (RTRs) is a challenging issue that has been discussed by many authors over the years, but evidence is sparse and often includes conflicting reports. Among the therapeutic options for PCa in these patients, prostate irradiation represents a valuable alternative to surgery or other systemic therapies, as RTRs are often ineligible for these treatments. To report six cases treated at our institution between 1998 and 2017 and discuss the available literature. Patients' characteristics were reported along with biochemical status at diagnosis, type of immunosuppressive treatment, radiation therapy technique, and dose to transplanted kidney. Overall, prostate irradiation was delivered respecting the dose constraints and patients showed good tolerance with no reports of acute or late transplanted kidney injury. Our experience confirms that prostate radiotherapy for RTRs is feasible and effective and represents a valid option that should be considered by the multidisciplinary team.

Sections du résumé

BACKGROUND UNASSIGNED
Patients who received a kidney transplant (KT) are described in literature as a group with a higher incidence of malignant neoplasms compared to the general population. Cancer development after KT has become a major issue, as a remarkable percentage of patients are diagnosed with cancer. Treatment of prostate cancer (PCa) in renal transplant recipients (RTRs) is a challenging issue that has been discussed by many authors over the years, but evidence is sparse and often includes conflicting reports. Among the therapeutic options for PCa in these patients, prostate irradiation represents a valuable alternative to surgery or other systemic therapies, as RTRs are often ineligible for these treatments.
OBJECTIVE UNASSIGNED
To report six cases treated at our institution between 1998 and 2017 and discuss the available literature.
METHODS UNASSIGNED
Patients' characteristics were reported along with biochemical status at diagnosis, type of immunosuppressive treatment, radiation therapy technique, and dose to transplanted kidney.
RESULTS UNASSIGNED
Overall, prostate irradiation was delivered respecting the dose constraints and patients showed good tolerance with no reports of acute or late transplanted kidney injury.
CONCLUSIONS UNASSIGNED
Our experience confirms that prostate radiotherapy for RTRs is feasible and effective and represents a valid option that should be considered by the multidisciplinary team.

Identifiants

pubmed: 34057383
doi: 10.1177/03008916211013914
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

371-375

Auteurs

Beatrice Detti (B)

Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

Giulia Stocchi (G)

Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

Matteo Mariotti (M)

Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

Angela Sardaro (A)

Interdisciplinary Department of Medicine, Nuclear Medicine Unit and Section of Radiology and Radiation Oncology, University of Bari Aldo Moro, Bari, Italy.

Giulio Francolini (G)

Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

Andrea G Allegra (AG)

Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

Manuele Roghi (M)

Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

Virginia Maragna (V)

Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

Maria A Teriaca (MA)

Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

Lorenzo Livi (L)

Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH